Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 3.904
Filtrar
1.
J Agric Food Chem ; 72(20): 11360-11368, 2024 May 22.
Artículo en Inglés | MEDLINE | ID: mdl-38720533

RESUMEN

In this study, a series of acrylamide derivatives containing trifluoromethylpyridine or piperazine fragments were rationally designed and synthesized. Subsequently, the in vitro antifungal activities of all of the synthesized compounds were evaluated. The findings revealed that compounds 6b, 6c, and 7e exhibited >80% antifungal activity against Phomopsis sp. (Ps) at the concentration of 50 µg/mL. Furthermore, the EC50 values for compounds 6b, 6c, and 7e against Ps were determined to be 4.49, 6.47, and 8.68 µg/mL, respectively, which were better than the positive control with azoxystrobin (24.83 µg/mL). At the concentration of 200 µg/mL, the protective activity of compound 6b against Ps reached 65%, which was comparable to that of azoxystrobin (60.9%). Comprehensive mechanistic studies, including morphological studies with fluorescence microscopy (FM), cytoplasmic leakage, and enzyme activity assays, indicated that compound 6b disrupts cell membrane integrity and induces the accumulation of defense enzyme activity, thereby inhibiting mycelial growth. Therefore, compound 6b serves as a valuable candidate for the development of novel fungicides for plant protection.


Asunto(s)
Acrilamida , Diseño de Fármacos , Fungicidas Industriales , Piridinas , Fungicidas Industriales/farmacología , Fungicidas Industriales/síntesis química , Fungicidas Industriales/química , Acrilamida/química , Piridinas/química , Piridinas/farmacología , Piridinas/síntesis química , Relación Estructura-Actividad , Ascomicetos/efectos de los fármacos , Ascomicetos/crecimiento & desarrollo , Piperazina/química , Piperazina/farmacología , Piperazinas/farmacología , Piperazinas/química , Piperazinas/síntesis química , Estructura Molecular , Pruebas de Sensibilidad Microbiana , Enfermedades de las Plantas/microbiología
2.
ACS Chem Biol ; 19(5): 1180-1193, 2024 May 17.
Artículo en Inglés | MEDLINE | ID: mdl-38652683

RESUMEN

C. elegans numr-1/2 (nuclear-localized metal-responsive) is an identical gene pair encoding a nuclear protein previously shown to be activated by cadmium and disruption of the integrator RNA metabolism complex. We took a chemical genetic approach to further characterize regulation of this novel metal response by screening 41,716 compounds and extracts for numr-1p::GFP activation. The most potent activator was chaetocin, a fungal 3,6-epidithiodiketopiperazine (ETP) with promising anticancer activity. Chaetocin activates numr-1/2 strongly in the alimentary canal but is distinct from metal exposure, because it represses canonical cadmium-responsive metallothionine genes. Chaetocin has diverse targets in cancer cells including thioredoxin reductase, histone lysine methyltransferase, and acetyltransferase p300/CBP; further work is needed to identify the mechanism in C. elegans as genetic disruption and RNAi screening of homologues did not induce numr-1/2 in the alimentary canal and chaetocin did not affect markers of integrator dysfunction. We demonstrate that disulfides in chaetocin and chetomin, a dimeric ETP analog, are required to induce numr-1/2. ETP monomer gliotoxin, despite possessing a disulfide linkage, had almost no effect on numr-1/2, suggesting a dimer requirement. Chetomin inhibits C. elegans growth at low micromolar levels, and loss of numr-1/2 increases sensitivity; C. elegans and Chaetomiaceae fungi inhabit similar environments raising the possibility that numr-1/2 functions as a defense mechanism. There is no direct orthologue of numr-1/2 in humans, but RNaseq suggests that chaetocin affects expression of cellular processes linked to stress response and metal homeostasis in colorectal cancer cells. Our results reveal interactions between metal response gene regulation and ETPs and identify a potential mechanism of resistance to this versatile class of preclinical compounds.


Asunto(s)
Proteínas de Caenorhabditis elegans , Caenorhabditis elegans , Homeostasis , Micotoxinas , Caenorhabditis elegans/efectos de los fármacos , Caenorhabditis elegans/genética , Caenorhabditis elegans/metabolismo , Animales , Proteínas de Caenorhabditis elegans/metabolismo , Proteínas de Caenorhabditis elegans/genética , Micotoxinas/farmacología , Micotoxinas/metabolismo , Homeostasis/efectos de los fármacos , Antineoplásicos/farmacología , Antineoplásicos/química , Piperazinas/farmacología , Piperazinas/química , Humanos , Proteínas Nucleares/metabolismo , Proteínas Nucleares/genética , Cadmio/farmacología
3.
Molecules ; 29(8)2024 Apr 13.
Artículo en Inglés | MEDLINE | ID: mdl-38675599

RESUMEN

We introduced a terminal alkyne into the core structure of dolutegravir, resulting in the synthesis of 34 novel dolutegravir-1,2,3-triazole compounds through click chemistry. These compounds exhibited remarkable inhibitory activities against two hepatocellular carcinoma cell lines, Huh7 and HepG2. Notably, compounds 5e and 5p demonstrated exceptional efficacy, particularly against Huh7 cells, with IC50 values of 2.64 and 5.42 µM. Additionally, both compounds induced apoptosis in Huh7 cells, suppressed tumor cell clone formation, and elevated reactive oxygen species (ROS) levels, further promoting tumor cell apoptosis. Furthermore, compounds 5e and 5p activated the LC3 signaling pathway, inducing autophagy, and triggered the γ-H2AX signaling pathway, resulting in DNA damage in tumor cells. Compound 5e exhibited low toxicity, highlighting its potential as a promising anti-tumor drug.


Asunto(s)
Antineoplásicos , Apoptosis , Autofagia , Daño del ADN , Compuestos Heterocíclicos con 3 Anillos , Neoplasias Hepáticas , Oxazinas , Piperazinas , Piridonas , Especies Reactivas de Oxígeno , Humanos , Piridonas/farmacología , Piridonas/química , Autofagia/efectos de los fármacos , Daño del ADN/efectos de los fármacos , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/patología , Piperazinas/farmacología , Piperazinas/química , Oxazinas/farmacología , Oxazinas/química , Compuestos Heterocíclicos con 3 Anillos/farmacología , Compuestos Heterocíclicos con 3 Anillos/química , Antineoplásicos/farmacología , Antineoplásicos/química , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Especies Reactivas de Oxígeno/metabolismo , Células Hep G2 , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/patología , Transducción de Señal/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Descubrimiento de Drogas
4.
Biomed Pharmacother ; 174: 116484, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38565058

RESUMEN

A novel small molecule based on benzothiazole-piperazine has been identified as an effective multi-target-directed ligand (MTDL) against Alzheimer's disease (AD). Employing a medicinal chemistry approach, combined with molecular docking, MD simulation, and binding free energy estimation, compound 1 emerged as a potent MTDL against AD. Notably, compound 1 demonstrated efficient binding to both AChE and Aß1-42, involving crucial molecular interactions within their active sites. It displayed a binding free energy (ΔGbind) -18.64± 0.16 and -16.10 ± 0.18 kcal/mol against AChE and Aß1-42, respectively. In-silico findings were substantiated through rigorous in vitro and in vivo studies. In vitro analysis confirmed compound 1 (IC50=0.42 µM) as an effective, mixed-type, and selective AChE inhibitor, binding at both the enzyme's catalytic and peripheral anionic sites. Furthermore, compound 1 demonstrated a remarkable ability to reduce the aggregation propensity of Aß, as evidenced by Confocal laser scanning microscopy and TEM studies. Remarkably, in vivo studies exhibited the promising therapeutic potential of compound 1. In a scopolamine-induced memory deficit mouse model of AD, compound 1 showed significantly improved spatial memory and cognition. These findings collectively underscore the potential of compound 1 as a promising therapeutic candidate for the treatment of AD.


Asunto(s)
Acetilcolinesterasa , Enfermedad de Alzheimer , Péptidos beta-Amiloides , Benzotiazoles , Inhibidores de la Colinesterasa , Simulación del Acoplamiento Molecular , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/metabolismo , Animales , Benzotiazoles/farmacología , Benzotiazoles/química , Inhibidores de la Colinesterasa/farmacología , Inhibidores de la Colinesterasa/química , Péptidos beta-Amiloides/metabolismo , Acetilcolinesterasa/metabolismo , Ratones , Masculino , Humanos , Piperazinas/farmacología , Piperazinas/química , Escopolamina , Piperazina/farmacología , Piperazina/química , Fragmentos de Péptidos/metabolismo , Fragmentos de Péptidos/farmacología , Simulación de Dinámica Molecular , Simulación por Computador , Modelos Animales de Enfermedad , Aprendizaje por Laberinto/efectos de los fármacos
5.
Spectrochim Acta A Mol Biomol Spectrosc ; 315: 124248, 2024 Jul 05.
Artículo en Inglés | MEDLINE | ID: mdl-38599026

RESUMEN

Ferroptosis is a type of lipid peroxidation-induced apoptosis brought on by imbalances in iron metabolism and redox. It involves both the thiol-associated anti-ferroptosis pathway and the excessive buildup of reactive oxygen species (ROS), which stimulates the ferroptosis pathway. Determining the precise control mechanism of ferroptosis requires examining the dynamic connection between reactive sulfur species (RSS) and ROS. Cysteine (Cys) and peroxynitrite (ONOO-) are highly active redox species in organisms and play dynamic roles in the ferroptosis process. In this study, a coumarin dye was conjugated with specific response sites for Cys and ONOO-, enabling the simultaneous detection of Cys and ONOO- through the green and red fluorescence channels, respectively (λem = 498 nm for Cys and λem = 565 nm for ONOO-). Using the probe LXB, we monitored the changes in Cys and ONOO- levels in the ferroptosis pathway induced by erastin. The results demonstrate a significant generation of ONOO- and a noticeable decrease in intracellular Cys levels at the beginning upon erastin treatment and finally maintains a relatively low level. This study presents the first probe to investigate the intracellular redox modulation and control between Cys and ONOO- during ferroptosis, providing valuable insights into the potential mutual correlation between Cys and ONOO- in this process.


Asunto(s)
Cisteína , Ferroptosis , Colorantes Fluorescentes , Ácido Peroxinitroso , Ferroptosis/efectos de los fármacos , Colorantes Fluorescentes/química , Cisteína/metabolismo , Cisteína/análisis , Humanos , Ácido Peroxinitroso/análisis , Ácido Peroxinitroso/metabolismo , Espectrometría de Fluorescencia , Oxidación-Reducción , Piperazinas/farmacología , Piperazinas/química , Cumarinas/química , Cumarinas/farmacología
6.
Biomater Sci ; 12(10): 2639-2647, 2024 May 14.
Artículo en Inglés | MEDLINE | ID: mdl-38563394

RESUMEN

Triple negative breast cancer (TNBC) exhibits limited responsiveness to immunotherapy owing to its immunosuppressive tumor microenvironment (TME). Here, a reactive oxygen species (ROS)-labile nanodrug encapsulating the photosensitizer Ce6 and Bcl-2 inhibitor ABT-737 was developed to provoke a robust immune response via the synergistic effect of photodynamic therapy (PDT) and the reversal of apoptosis resistance. Upon exposure to first-wave near-infrared laser irradiation, the generated ROS triggers PEG cleavage, facilitating the accumulation of the nanodrug at tumor region and endocytosis by tumor cells. Further irradiation leads to the substantial generation of cytotoxic ROS, initiating an immunogenic cell death (ICD) cascade, which prompts the maturation of dendritic cells (DCs) as well as the infiltration of T cells into the tumor site. Meanwhile, Bcl-2 inhibition counteracts apoptosis resistance, thereby amplifying PDT-induced ICD and bolstering antitumor immunity. As a result, the ROS-sensitive nanodrug demonstrates a potent inhibitory effect on tumor growth.


Asunto(s)
Apoptosis , Compuestos de Bifenilo , Inmunoterapia , Fotoquimioterapia , Fármacos Fotosensibilizantes , Especies Reactivas de Oxígeno , Sulfonamidas , Neoplasias de la Mama Triple Negativas , Neoplasias de la Mama Triple Negativas/terapia , Neoplasias de la Mama Triple Negativas/tratamiento farmacológico , Neoplasias de la Mama Triple Negativas/patología , Neoplasias de la Mama Triple Negativas/inmunología , Humanos , Apoptosis/efectos de los fármacos , Fármacos Fotosensibilizantes/farmacología , Fármacos Fotosensibilizantes/química , Fármacos Fotosensibilizantes/administración & dosificación , Femenino , Especies Reactivas de Oxígeno/metabolismo , Animales , Ratones , Compuestos de Bifenilo/farmacología , Compuestos de Bifenilo/química , Sulfonamidas/farmacología , Sulfonamidas/química , Clorofilidas , Línea Celular Tumoral , Piperazinas/farmacología , Piperazinas/química , Nitrofenoles/farmacología , Nitrofenoles/química , Nanopartículas/química , Porfirinas/farmacología , Porfirinas/química , Antineoplásicos/farmacología , Antineoplásicos/química
7.
J Pharmacol Exp Ther ; 389(3): 301-309, 2024 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-38621994

RESUMEN

δ opioid receptors (DORs) hold potential as a target for neurologic and psychiatric disorders, yet no DOR agonist has proven efficacious in critical phase II clinical trials. The exact reasons for the failure to produce quality drug candidates for the DOR are unclear. However, it is known that certain DOR agonists can induce seizures and exhibit tachyphylaxis. Several studies have suggested that those adverse effects are more prevalent in delta agonists that share the (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC80)/4-[(αR*)-α-((2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl]-N,N-diethylbenzamide chemotype. There is a need to find novel lead candidates for drug development that have improved pharmacological properties to differentiate them from the current failed delta agonists. Our objective in this study was to identify novel DOR agonists. We used a ß-arrestin assay to screen a small G-protein coupled receptors (GPCR)-focused chemical library. We identified a novel chemotype of DOR agonists that appears to bind to the orthosteric site based of docking and molecular dynamic simulation. The most potent agonist hit compound is selective for the DOR over a panel of 167 other GPCRs, is slightly biased toward G-protein signaling and has anti-allodynic efficacy in a complete Freund's adjuvant model of inflammatory pain in C57BL/6 male and female mice. The newly discovered chemotype contrasts with molecules like SNC80 that are highly efficacious ß-arrestin recruiters and may suggest this novel class of DOR agonists could be expanded on to develop a clinical candidate drug. SIGNIFICANCE STATEMENT: δ opioid receptors are a clinical target for various neurological disorders, including migraine and chronic pain. Many of the clinically tested delta opioid agonists share a single chemotype, which carries risks during drug development. Through a small-scale high-throughput screening assay, this study identified a novel δ opioid receptor agonist chemotype, which may serve as alternative for the current analgesic clinical candidates.


Asunto(s)
Receptores Opioides delta , Receptores Opioides delta/agonistas , Receptores Opioides delta/metabolismo , Animales , Ratones , Masculino , Humanos , Compuestos de Espiro/farmacología , Compuestos de Espiro/química , Piperazinas/farmacología , Piperazinas/química , Ratones Endogámicos C57BL , Simulación del Acoplamiento Molecular , Benzamidas/farmacología , Benzamidas/química , Cricetulus , beta-Arrestinas/metabolismo , Células HEK293 , Células CHO
8.
Chem Biol Interact ; 395: 111026, 2024 May 25.
Artículo en Inglés | MEDLINE | ID: mdl-38679115

RESUMEN

In the pursuit of novel antioxidant therapies for the prevention and treatment of neurodegenerative diseases, three new arylpiperazine derivatives (LQFM181, LQFM276, and LQFM277) were synthesized through a molecular hybridization approach involving piribedil and butylated hydroxytoluene lead compounds. To evaluate the antioxidant and neuroprotective activities of the arylpiperazine derivatives, we employed an integrated approach using both in vitro (SH-SY5Y cells) and in vivo (neurotoxicity induced by 3-nitropropionic acid in Swiss mice) models. In the in vitro tests, LQFM181 showed the most promising antioxidant activity at the neuronal membrane and cytoplasmic levels, and significant neuroprotective activity against the neurotoxicity induced by 3-nitropropionic acid. Hence, this compound was further subjected to in vivo evaluation, which demonstrated remarkable antioxidant capacity such as reduction of MDA and carbonyl protein levels, increased activities of succinate dehydrogenase, catalase, and superoxide dismutase. Interestingly, using the same in vivo model, LQFM181 also reduced locomotor behavior and memory dysfunction through its ability to decrease cholinesterase activity. Consequently, LQFM181 emerges as a promising candidate for further investigation into its neuroprotective potential, positioning it as a new therapeutic agent for neuroprotection.


Asunto(s)
Antioxidantes , Fármacos Neuroprotectores , Nitrocompuestos , Piperazinas , Propionatos , Animales , Propionatos/toxicidad , Nitrocompuestos/toxicidad , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/química , Ratones , Piperazinas/farmacología , Piperazinas/química , Humanos , Línea Celular Tumoral , Antioxidantes/farmacología , Masculino , Succinato Deshidrogenasa/metabolismo , Superóxido Dismutasa/metabolismo , Catalasa/metabolismo , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Malondialdehído/metabolismo , Estrés Oxidativo/efectos de los fármacos
9.
Bioorg Med Chem ; 105: 117716, 2024 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-38608329

RESUMEN

In this study, a series of new formylpiperazine-derived ferroptosis inhibitors were designed and synthesized based on the structure of a known ferroptosis inhibitor, ferrostatin-1 (Fer-1). The anti-ferroptosis activity of these synthetic compounds in human umbilical vein endothelial cells (HUVECs) induced by Erastin was evaluated. It was found that some of the new compounds, especially compound 26, showed potent anti-ferroptosis activity, as evidenced by its ability to restore cell viability, reduce iron accumulation, scavenge reactive oxygen species, maintain mitochondrial membrane potential, increase GSH levels, decrease LPO and MDA content, and upregulate GPX4 expression. Moreover, compound 26 exhibited superior microsomal stability than Fer-1. The present results suggest that compound 26 is a promising lead compound for the development of new ferroptosis inhibitors for the treatment of vascular diseases.


Asunto(s)
Supervivencia Celular , Ciclohexilaminas , Diseño de Fármacos , Ferroptosis , Células Endoteliales de la Vena Umbilical Humana , Piperazinas , Humanos , Ferroptosis/efectos de los fármacos , Piperazinas/farmacología , Piperazinas/síntesis química , Piperazinas/química , Células Endoteliales de la Vena Umbilical Humana/efectos de los fármacos , Relación Estructura-Actividad , Ciclohexilaminas/farmacología , Ciclohexilaminas/química , Ciclohexilaminas/síntesis química , Supervivencia Celular/efectos de los fármacos , Estructura Molecular , Fenilendiaminas/farmacología , Fenilendiaminas/química , Fenilendiaminas/síntesis química , Relación Dosis-Respuesta a Droga , Especies Reactivas de Oxígeno/metabolismo , Compuestos Ferrosos/farmacología , Compuestos Ferrosos/química , Compuestos Ferrosos/síntesis química , Potencial de la Membrana Mitocondrial/efectos de los fármacos
10.
Bioorg Med Chem ; 103: 117682, 2024 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-38493729

RESUMEN

Zika virus (ZIKV) disease has been given attention due to the risk of congenital microcephaly and neurodevelopmental disorders after ZIKV infection in pregnancy, but no vaccine or antiviral drug is available. Based on a previously reported ZIKV inhibitor ZK22, a series of novel 1-aryl-4-arylmethylpiperazine derivatives was designed, synthesized, and investigated for antiviral activity by quantify cellular ZIKV RNA amount using RT-qPCR method in ZIKV-infected human venous endothelial cells (HUVECs) assay. Structure-activity relationship (SAR) analysis demonstrated that anti-ZIKV activity of 1-aryl-4-arylmethylpiperazine derivatives is not correlated with molecular hydrophobicity, multiple new derivatives with pyridine group to replace the benzonitrile moiety of ZK22 showed stronger antiviral activity, higher ligand lipophilicity efficiency as well as lower cytotoxicity. Two active compounds 13 and 33 were further identified as novel ZIKV entry inhibitors with the potential of oral available. Moreover, both ZK22 and newly active derivatives also possess of obvious inhibition on the viral replication of coronavirus and influenza A virus at low micromolar level. In summary, this work provided better candidates of ZIKV inhibitor for preclinical study and revealed the promise of 1-aryl-4-arylmethylpiperazine chemotype in the development of broad-spectrum antiviral agents.


Asunto(s)
Infección por el Virus Zika , Virus Zika , Femenino , Humanos , Embarazo , Antivirales/farmacología , Antivirales/uso terapéutico , Células Endoteliales , Replicación Viral , Infección por el Virus Zika/tratamiento farmacológico , Piperazinas/química , Piperazinas/farmacología
11.
Bioorg Med Chem ; 104: 117698, 2024 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-38552597

RESUMEN

Serotonin reuptake inhibition combined with the action targeting 5-hydroxytryptamine receptor subtypes can serve as a potential target for the development of antidepressant drugs. Herein a series of new aralkyl piperazines and piperidines were designed and synthesized by the structural modifications of the previously discovered aralkyl piperidine compound 1, targeting SSRI/5-HT1A/5-HT7. The results exhibited that compound 5a showed strong binding to 5-HT1A and 5-HT7 (Ki of 0.46 nM, 2.7 nM, respectively) and a high level of serotonin reuptake inhibition (IC50 of 1.9 nM), all of which were significantly elevated compared to 1. In particular, compound 5a showed weaker inhibitory activity against hERG than 1, and demonstrated good stability in liver microsomes in vitro. The preliminary screening using FST indicated that orally administered 5a, at a high dose, could reduce immobility time in mice markedly, indicating potential antidepressant activity.


Asunto(s)
Inhibidores Selectivos de la Recaptación de Serotonina , Serotonina , Ratones , Animales , Piperazina/farmacología , Serotonina/metabolismo , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Antidepresivos/farmacología , Antidepresivos/uso terapéutico , Piperidinas/farmacología , Piperazinas/química , Receptor de Serotonina 5-HT1A
12.
Angew Chem Int Ed Engl ; 63(20): e202401324, 2024 May 13.
Artículo en Inglés | MEDLINE | ID: mdl-38499463

RESUMEN

We report the discovery and biosynthesis of new piperazine alkaloids-arizonamides, and their derived compounds-arizolidines, featuring heterobicyclic and spirocyclic isoquinolone skeletons, respectively. Their biosynthetic pathway involves two crucial non-heme iron enzymes, ParF and ParG, for core skeleton construction. ParF has a dual function facilitating 2,3-alkene formation of helvamide, as a substrate for ParG, and oxidative cleavage of piperazine. Notably, ParG exhibits catalytic versatility in multiple oxidative reactions, including cyclization and ring reconstruction. A key amino acid residue Phe67 was characterized to control the formation of the constrained arizonamide B backbone by ParG.


Asunto(s)
Alcaloides , Alcaloides/química , Alcaloides/metabolismo , Alcaloides/biosíntesis , Piperazinas/química , Piperazinas/metabolismo , Hierro/química , Hierro/metabolismo , Ciclización , Biocatálisis , Estructura Molecular , Compuestos de Espiro/química , Compuestos de Espiro/metabolismo , Oxidación-Reducción , Piperazina/química , Piperazina/metabolismo
13.
Angew Chem Int Ed Engl ; 63(22): e202404000, 2024 May 27.
Artículo en Inglés | MEDLINE | ID: mdl-38527935

RESUMEN

Cytochrome P450 (CYP450)-catalyzed oxidative coupling is an efficient strategy for using simple building blocks to construct complex structural scaffolds of natural products. Among them, heterodimeric coupling between two different monomers is relatively scarce, and the corresponding CYP450s are largely undiscovered. In this study, we discovered a fungal CYP450 (CpsD) and its associated cps cluster from 37208 CYP450s of Pfam PF00067 family member database and subsequently identified a group of new skeleton indole piperazine alkaloids (campesines A-G) by combination of genome mining and heterologous synthesis. Importantly, CYP450 CpsD mainly catalyzes intermolecular oxidative heterocoupling of two different indole piperazine monomers to generate an unexpected 6/5/6/6/6/6/5/6 eight-ring scaffold through the formation of one C-C bond and two C-N bonds, illuminating its first dimerase role in this family of natural products. The proposed catalytic mechanism of CpsD was deeply investigated by diversified substrate derivatization. Moreover, dimeric campesine G shows good insecticidal activity against the global honeybee pest Galleria mellonella. Our study shows a representative example of discovering new skeleton monomeric and dimeric indole piperazine alkaloids from microbial resources, expands our knowledge of bond formation by CYP450s and supports further development of the newly discovered and engineered campesine family compounds as potential biopesticides.


Asunto(s)
Sistema Enzimático del Citocromo P-450 , Insecticidas , Oxidación-Reducción , Piperazinas , Sistema Enzimático del Citocromo P-450/metabolismo , Sistema Enzimático del Citocromo P-450/química , Piperazinas/química , Piperazinas/metabolismo , Piperazinas/farmacología , Insecticidas/química , Insecticidas/metabolismo , Insecticidas/farmacología , Animales , Alcaloides Indólicos/química , Alcaloides Indólicos/metabolismo , Biocatálisis , Alcaloides/química , Alcaloides/metabolismo , Alcaloides/farmacología , Estructura Molecular , Dimerización
14.
Pest Manag Sci ; 80(6): 2710-2723, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38358029

RESUMEN

BACKGROUND: Xanthomonas oryzae pv. oryzae (Xoo) is often considered one of the most destructive bacterial pathogens causing bacterial leaf blight (BLB), resulting in significant yield and cost losses in rice. In this study, a series of novel derivatives containing the isopropanolamine moiety linked to various substituted phenols and piperazines were designed, synthesized and screened. RESULTS: Antibacterial activity results showed that most compounds had good inhibitory effects on Xoo, among which compound W2 (EC50 = 2.74 µg mL-1) exhibited the most excellent inhibitory activity, and W2 also had a certain curative effect (35.89%) on rice compared to thiodiazole copper (TC) (21.57%). Scanning electron microscopy (SEM) results indicated that compound W2 could cause rupture of the Xoo cell membrane. Subsequently, proteomics and quantitative real-time polymerase chain reaction revealed that compound W2 affected the physiological processes of Xoo and may exert antibacterial activity by targeting the two-component system pathway. Interestingly, W2 upregulated Xoo's methyltransferase to impact on its pathogenicity. CONCLUSION: The present study offers a promising phenolic-piperazine-sopropanolamine compound as an innovative antibacterial strategy by specifically targeting the two-component system pathway and inducing upregulation of methyltransferase to effectively impact Xoo's pathogenicity. © 2024 Society of Chemical Industry.


Asunto(s)
Antibacterianos , Xanthomonas , Xanthomonas/efectos de los fármacos , Antibacterianos/farmacología , Antibacterianos/síntesis química , Antibacterianos/química , Fenoles/farmacología , Fenoles/química , Diseño de Fármacos , Piperazinas/farmacología , Piperazinas/química , Piperazinas/síntesis química , Oryza/microbiología , Enfermedades de las Plantas/microbiología
15.
Drug Discov Ther ; 17(6): 428-433, 2024 Jan 12.
Artículo en Inglés | MEDLINE | ID: mdl-38044120

RESUMEN

Olaparib is a small-molecule inhibitor of poly(ADP)-ribose polymerase (PARP) used as maintenance therapy for recurrent ovarian cancer and newly diagnosed advanced ovarian cancer after initial chemotherapy. An exposure-toxicity correlation has been reported between the probability of anemia, a common adverse event associated with olaparib, and the steady-state minimum plasma concentration (Cmin) as well as the predicted maximum plasma concentration (Cmax). On the other hand, olaparib exhibits high interpatient variability with regard to the area under the concentration-time curve, Cmax, and Cmin. Therefore, we developed a simple and sensitive assay based on high-performance liquid chromatography with ultraviolet light (HPLC-UV) for the therapeutic drug monitoring of olaparib. The analysis was performed on an octadecylsilyl column with a mobile phase consisting of 0.5% KH2PO4 (pH 4.5) and acetonitrile (71:29, v/v), at a flow rate of 0.8 mL/min. Olaparib and an internal standard (imatinib) were well separated from the co-extracted material, with retention times of 13.6 and 11.5 min, respectively. The calibration curve for olaparib showed linearity over the concentration range of 0.10-10.0 µg/mL (r2 = 0.9998). The intra- and inter- day validation coefficients ranged from 1.79 to 4.13% and 1.37 to 3.55%, respectively. Measurement accuracy ranged from - 6.07 to 3.26%, with a recovery rate of more than 91.06%. The developed method was then applied to evaluate the plasma olaparib concentrations in patients with ovarian cancer. Our findings demonstrate that HPLC-UV is an economical, simple, and sensitive method for clinical application and holds promise for the effective drug monitoring of olaparib during ovarian cancer treatment.


Asunto(s)
Neoplasias Ováricas , Ftalazinas , Inhibidores de Poli(ADP-Ribosa) Polimerasas , Humanos , Femenino , Cromatografía Líquida de Alta Presión/métodos , Inhibidores de Poli(ADP-Ribosa) Polimerasas/efectos adversos , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/inducido químicamente , Piperazinas/efectos adversos , Piperazinas/química
16.
Chembiochem ; 25(6): e202300770, 2024 03 15.
Artículo en Inglés | MEDLINE | ID: mdl-38116907

RESUMEN

Epidithiodioxopiperazine (ETP) alkaloids, featuring a 2,5-diketopiperazine core and transannular disulfide bridge, exhibit a broad spectrum of biological activities. However, the structural complexity has prevented efficient chemical synthesis and further clinical research. In the past few decades, many achievements have been made in the biosynthesis of ETPs. Here, we discuss the biosynthetic progress and summarize them as two comprehensible metabolic principles for better understanding the complex pathways of α, α'- and α, ß'-disulfide bridged ETPs. Specifically, we systematically outline the catalytic machineries to install α, α'- and α, ß'-disulfide by flavin-containing oxygenases. This concept would contribute to the medical and industrial applications of ETPs.


Asunto(s)
Disulfuros , Piperazinas , Disulfuros/química , Piperazinas/química
17.
Int J Mol Sci ; 24(14)2023 Jul 22.
Artículo en Inglés | MEDLINE | ID: mdl-37511552

RESUMEN

Piperazine is one of the most frequently found scaffolds in small-molecule FDA-approved drugs. In this study, a general approach to the synthesis of piperazines bearing substituents at carbon and nitrogen atoms utilizing primary amines and nitrosoalkenes as synthons was developed. The method relies on sequential double Michael addition of nitrosoalkenes to amines to give bis(oximinoalkyl)amines, followed by stereoselective catalytic reductive cyclization of the oxime groups. The method that we developed allows a straightforward structural modification of bioactive molecules (e.g., α-amino acids) by the conversion of a primary amino group into a piperazine ring.


Asunto(s)
Aminas , Piperazinas , Piperazina , Ciclización , Piperazinas/química , Aminas/química , Aminoácidos
18.
Molecules ; 28(10)2023 May 22.
Artículo en Inglés | MEDLINE | ID: mdl-37241965

RESUMEN

Fenebrutinib is an orally available Bruton tyrosine kinase inhibitor. It is currently in multiple phase III clinical trials for the management of B-cell tumors and autoimmune disorders. Elementary in-silico studies were first performed to predict susceptible sites of metabolism and structural alerts for toxicities by StarDrop WhichP450™ module and DEREK software; respectively. Fenebrutinib metabolites and adducts were characterized in-vitro in rat liver microsomes (RLM) using MS3 method in Ion Trap LC-MS/MS. Formation of reactive and unstable intermediates was explored using potassium cyanide (KCN), glutathione (GSH) and methoxylamine as trapping nucleophiles to capture the transient and unstable iminium, 6-iminopyridin-3(6H)-one and aldehyde intermediates, respectively, to generate a stable adducts that can be investigated and analyzed using mass spectrometry. Ten phase I metabolites, four cyanide adducts, five GSH adducts and six methoxylamine adducts of fenebrutinib were identified. The proposed metabolic reactions involved in formation of these metabolites are hydroxylation, oxidation of primary alcohol to aldehyde, n-oxidation, and n-dealkylation. The mechanism of reactive intermediate formation of fenebrutinib can provide a justification of the cause of its adverse effects. Formation of iminium, iminoquinone and aldehyde intermediates of fenebrutinib was characterized. N-dealkylation followed by hydroxylation of the piperazine ring is proposed to cause the bioactivation to iminium intermediates captured by cyanide. Oxidation of the hydroxymethyl group on the pyridine moiety is proposed to cause the generation of reactive aldehyde intermediates captures by methoxylamine. N-dealkylation and hydroxylation of the pyridine ring is proposed to cause formation of iminoquinone reactive intermediates captured by glutathione. FBB and several phase I metabolites are bioactivated to fifteen reactive intermediates which might be the cause of adverse effects. In the future, drug discovery experiments utilizing this information could be performed, permitting the synthesis of new drugs with better safety profile. Overall, in silico software and in vitro metabolic incubation experiments were able to characterize the FBB metabolites and reactive intermediates using the multistep fragmentation capability of ion trap mass spectrometry.


Asunto(s)
Piperazinas , Espectrometría de Masas en Tándem , Ratas , Animales , Cromatografía Liquida , Cromatografía Líquida de Alta Presión/métodos , Espectrometría de Masas en Tándem/métodos , Piperazinas/química , Piridonas/análisis , Glutatión/metabolismo , Cianuros/análisis , Aldehídos/análisis , Microsomas Hepáticos/metabolismo
19.
Chem Biodivers ; 20(4): e202201087, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-36919620

RESUMEN

Endophytic fungi possess a versatile metabolism which is related to their ability to live in diverse ecological niches. While culturing under laboratory conditions, their metabolism is mainly influenced by the culture media, time of incubation and other physicochemical factors. In this study, we focused on the production of 3 thiodiketopiperazines (TDKPs) botryosulfuranols A-C produced by an endophytic strain of Cophinforma mamane isolated from the leaves of Bixa orellana L collected in the Peruvian Amazon. We studied the time-course production of botryosulfuranols A-C during 28 days and evaluated the variations in the production of secondary metabolites, including the TDKPs, produced by C. mamane in response to different culture media, light versus dark conditions and different incubation times. We observed a short time-frame production of botryosulfuranol C while its production was significantly affected by the light conditions and nutrients of the culture media. Botryosulfuranols A and B showed a similar production pattern and a similar response to culturing conditions. Molecular networking allowed us to detect three compounds related to TDKPs that will be the focus of future experiments.


Asunto(s)
Ascomicetos , Endófitos , Piperazinas , Ascomicetos/química , Bixaceae/microbiología , Endófitos/metabolismo , Hongos/metabolismo , Piperazinas/química
20.
Eur J Med Chem ; 245(Pt 1): 114906, 2023 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-36395647

RESUMEN

We have already reported the modification on the piperazine and phenyl rings of JNJ4796, a small-molecule fuse inhibitor targeting hemagglutinin (HA). In this study, we described the structure-activity relationship of the benzoxazole and tetrazole rings of JNJ4796. Many derivatives demonstrated good in vitro activity against IAV H1N1and Oseltamivir-resistant IAV H1N1 stains. Although compounds (R)-1e and (R)-1h exhibited excellent in vitro activity, high drug exposure level and low hERG inhibition, they displayed low oral efficacy. Excitedly, (R)-1a, a representative identified in our previous study, was found to show potent in vivo anti-IAV activity with the survival rates of 100%, 100% and 70% at 15, 5 and 1.67 mg/kg, respectively, comparable to JNJ4796. Currently, we are exploring different ways to ease its gastrointestinal response.


Asunto(s)
Antivirales , Benzoxazoles , Subtipo H1N1 del Virus de la Influenza A , Piperazinas , Tetrazoles , Benzoxazoles/química , Benzoxazoles/farmacología , Subtipo H1N1 del Virus de la Influenza A/efectos de los fármacos , Piperazinas/química , Piperazinas/farmacología , Tetrazoles/química , Tetrazoles/farmacología , Relación Estructura-Actividad , Antivirales/química , Antivirales/farmacología , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...